1. Home
  2. ETNB vs UWMC Comparison

ETNB vs UWMC Comparison

Compare ETNB & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • UWMC
  • Stock Information
  • Founded
  • ETNB 2018
  • UWMC 1986
  • Country
  • ETNB United States
  • UWMC United States
  • Employees
  • ETNB N/A
  • UWMC N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • UWMC Finance: Consumer Services
  • Sector
  • ETNB Health Care
  • UWMC Finance
  • Exchange
  • ETNB Nasdaq
  • UWMC Nasdaq
  • Market Cap
  • ETNB 1.5B
  • UWMC 1.4B
  • IPO Year
  • ETNB 2019
  • UWMC N/A
  • Fundamental
  • Price
  • ETNB $8.87
  • UWMC $6.32
  • Analyst Decision
  • ETNB Strong Buy
  • UWMC Hold
  • Analyst Count
  • ETNB 10
  • UWMC 7
  • Target Price
  • ETNB $27.22
  • UWMC $5.54
  • AVG Volume (30 Days)
  • ETNB 1.5M
  • UWMC 10.0M
  • Earning Date
  • ETNB 11-06-2025
  • UWMC 11-06-2025
  • Dividend Yield
  • ETNB N/A
  • UWMC 6.34%
  • EPS Growth
  • ETNB N/A
  • UWMC 112.84
  • EPS
  • ETNB N/A
  • UWMC 0.07
  • Revenue
  • ETNB N/A
  • UWMC $2,622,828,000.00
  • Revenue This Year
  • ETNB N/A
  • UWMC $25.96
  • Revenue Next Year
  • ETNB N/A
  • UWMC N/A
  • P/E Ratio
  • ETNB N/A
  • UWMC $95.20
  • Revenue Growth
  • ETNB N/A
  • UWMC 13.45
  • 52 Week Low
  • ETNB $4.16
  • UWMC $3.80
  • 52 Week High
  • ETNB $11.84
  • UWMC $9.25
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 43.45
  • UWMC 73.14
  • Support Level
  • ETNB $8.46
  • UWMC $5.50
  • Resistance Level
  • ETNB $9.47
  • UWMC $5.78
  • Average True Range (ATR)
  • ETNB 0.46
  • UWMC 0.22
  • MACD
  • ETNB -0.02
  • UWMC 0.02
  • Stochastic Oscillator
  • ETNB 33.33
  • UWMC 94.60

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About UWMC UWM Holdings Corporation

UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.

Share on Social Networks: